BREAST CANCER

**SWOG S0800:** A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel(NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PRG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer.

PI: Mayer Gorbaty, M.D.

**S1007:** A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

PI: Mukund Didolkar, M.D.

**SCUSF 0806:** Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to reduce cardiotoxicity in Patients with Breast Cancer Receiving (neo) Adjuvant Chemotherapy with trastuzumab (Herceptin®).

PI: Mayer Gorbaty, M.D.

**S0927:** A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III

PI: Mayer Gorbaty, M.D.

**CA191-011:** A Phase 2 Study of BMS-754807 combined with Letrozole or BMS-754807 alone in Hormone-Receptor Positive Breast Cancer Subjects with Acquired Resistance to Non-Steroidal Aromatase Inhibitors

PI: Mayer Gorbaty, M.D.

**NSABP B-47:** A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

PI: Mayer Gorbaty, M.D.

**NSABP B-43:** A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

PI: Mayer Gorbaty, M.D.

Metastatic Breast Cancer

**E2108:** A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer.

PI: Mayer Gorbaty, M.D.

**N093B:** Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer

PI: Mayer Gorbaty, M.D.

GYNAECOLOGICAL CANCER

**ChemoFX Observational Study:** A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies.

PI: Fouad Abbas, M.D.

Uterine

**GOG-0238:** A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. PI: Fouad Abbas, M.D.

**GOG-0261:** A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus. PI: Fouad Abbas, M.D.
GOG-0170Q: A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer. 
Pl: Fouad Abbas, M.D.

GOG-0186I: A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) And Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) (NSC #752293) In the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Pl: Mark Miller, D.O.

GOG-0186J: A Randomized Phase IIIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo In The Treatment Of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Pl: Mark Miller, D.O.

Cervical

Endometrial

GOG-0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer.
Pl: Fouad Abbas, M.D.

GOG-0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
Pl: Fouad Abbas, M.D.

LUNG CANCER

NSCLC

ACCL001.0: A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non –Small Cell Cancer. 
Pl: Jeanette Linder, MD

SWOG S0819: A Randomized, Phase II Study Comparing Carboplatin/Paclitaxel or Carboplatin/ Paclitaxel/Bevacizumab with or without Cetuximab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC).
Pl: Roberto Martinez, M.D.

ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC).
Pl: Roberto Martinez, M.D.

CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COSX-2 Inhibition in COS-2 Expressing Advanced Non-Small Cell Lung Cancer. 
Pl: Roberto Martinez, M.D.

ECOG E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Pl: Roberto Martinez

Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy 
Pl: Roberto Martinez, M.D.

SCLC

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.
Pl: Roberto Martinez, M.D.
GASTROINTESTINAL CANCERS

Colon

**CALGB/SWOG C80702:** A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib Or Placebo for Patients with Resected Stage III Colon Cancer  
**PI:** Mayer Gorbaty, M.D.

Metastatic Colon Cancer

**NCCTG N0949:** Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer  
**PI:** Mayer Gorbaty, M.D.

GIST

**ABO4030:** a Prospective, Multicenter, Randomized, Open-Label, Active Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib At 7.5 mg/kg/day to Imatinib at 400 or 600 mg in Treatment of Patients with Gastro-Intestinal Stromal Tumor in First Line Medical Treatment.  
**PI:** Mukund Didolkar, MD

**IMCL CP15-1008:** A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST). **PI:** Mukund Didolkar, M.D.

Pancreatic

**ACOSOG Z5041:** A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma  
**PI:** Mukund Didolkar, M.D.

**RTOG 0848:** A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.  
**PI:** Mayer Gorbaty, M.D.

PROSTATE

**ACCP001.0:** Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution. **PI:** Jeanette Linder, M.D.

ORTHOPAEDIC ONCOLOGY

Comparing CT-Based Structural Rigidity Analysis (SRA) to Current Clinical and Radiological Methods for Selecting Treatment Options for Patients with Skeletal Metastasis  
**PI:** Albert Aboulafia, M.D.

**2005LS080:** An Evaluation of PET/CT Imaging As A Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy For Soft Tissue Sarcoma.  
**PI:** Albert Aboulafia, M.D.

The Use of Microarray in Characterizing Mesenchymal Tumors: Differentiation of Normal, Benign, and Malignant Conditions.  
**PI:** Albert Aboulafia, M.D.

**ET743-SAR-3007:** A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma  
**PI:** Albert Aboulafia, M.D.
LYMPHOMA

Diffuse Large B-Cell

**CO5013**: An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma.
PI: Joseph Wiley, M.D.

**CALGB 50303**: “Phase III Randomized Study of R-CHOP versus Dose- Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas.
PI: Roberto Martinez, M.D.

Hodgkin Lymphoma

**S0816**: "A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging"
PI: Roberto Martinez, M.D.

MELANOMA

**ECOG E1609**: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
PI: Mukund Didolkar, M.D.

SUPPORTIVE CARE

**MDA 2007-0914A (PREDICT)**: A Multi-Center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment.
PI: Joseph Wiley, M.D.

**Shire Gaucher Disease Outcome Survey (GOS)**
Using data collected to better understand the course of the disease, how it is treated and possibly improve how patients are cared for.
PI: Joseph Wiley, M.D.

**Survivorship Care Study**: A Study of the Impact of Survivorship Care by Medical and Radiation Oncology Nurses for Cancer Survivors during the End of Active Treatment
PI: Kenneth Miller, M.D.

**TCREG-001-00-V2-1209**: “A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients.”
PI: Fouad Abbas, M.D.

**CPS-3**: Cancer Prevention Study-3 (American Cancer Society)
PI: Kenneth Miller, M.D.